Policy Notices

• AHRQ Guide Notice on Exception to the Use of the Single IRB Review Requirements During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
  (NOT-HS-21-002)
  Agency for Healthcare Research and Quality
  

• Notice of Office of Laboratory Animal Welfare Statement on Oversight of NIH-owned Chimpanzees
  (NOT-OD-21-022)
  National Institutes of Health
  

• Extended Guidance for Applicants Preparing Applications During the COVID-19 Pandemic
  (NOT-OD-21-026)
  National Institutes of Health
  

General Notices

• Pre-Application Webinar for NOT-CA-21-008, Notice of Special Interest (NOSI): Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data
  (NOT-CA-21-010)
  National Cancer Institute
  

• Pre-Application Webinar for RFA-CA-20-043 "Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01 Clinical Trial Not Allowed) "
  (NOT-CA-21-015)
  National Cancer Institute
  

• The NIH Office of Disease Prevention (ODP) Announces the Pathways to Prevention Workshop: Can Physical Activity Improve the Health of Wheelchair Users?
  (NOT-OD-21-024)
  Office of Disease Prevention
  

Notice of Changes to Funding Opportunities

• NIA Withdraws Participation in NOT-AG-20-022 - NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  (NOT-AG-20-054)
  National Institute on Aging
  

• Notice of Extension of the Expiration Date for PAR-18-530 "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)"
  (NOT-CA-21-007)
  National Cancer Institute
  

• Notice to Extend the Expiration Date for PAR-18-656, NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  (NOT-DE-20-036)
  National Institute of Dental and Craniofacial Research
  

• Notice of Correction to Specific Areas of Research Interest for PAR-20-168 "Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)"
  (NOT-NS-21-013)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional)
  (NOT-AA-20-023)
  National Institute on Alcohol Abuse and Alcoholism
  

Requests for Proposal

• Presolicitation Notice: Request for Proposals (RFP) 75N91021R00007 "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients"
  (NOT-CA-21-011)
  National Cancer Institute
  

• Presolicitation Notice: Request for Proposals (RFP) 75N91021R00003 "Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications"
  (NOT-CA-21-012)
  National Cancer Institute
  

• Presolicitation Notice: Request for Proposals (RFP) 75N91021R00004"Preclinical Toxicology of Large Molecule Drugs Developed for Cancer and Other Indications"
  (NOT-CA-21-013)
  National Cancer Institute
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data
  (NOT-CA-21-008)
  National Cancer Institute
  

Funding Opportunities

• Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional)
  (PAR-20-315)
  National Institutes of Health
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Rolling receipt dates: December 6, 2020 January 31, 2021; February 1, 2021 May 31, 2021; June 1, 2021 September 30, 2021; October 1, 2021 January 31, 2022; February 1, 2022 May 31, 2022; June 1, 2022 September 30, 2022; October 1, 2022- January 31, 2023; February 1, 2023 - May 31, 2023; June 1, 2023 September 30, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)
  (RFA-MD-21-001)
  National Institute on Minority Health and Health Disparities
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)
  (RFA-MD-21-002)
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)
  (RFA-RM-21-007)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): February 19, 2021 No late applications will be accepted for this Funding Opportunity Announcement.